Nifty
Sensex
:
:
11341.65
37766.32
-115.25 (-1.01%)
-398.29 (-1.04%)

Pharmaceuticals & Drugs

Rating :
74/99  (View)

BSE: 533573 | NSE: APLLTD

540.00
-0.25 (-0.05%)
25-Mar-2019 | 1:49PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  540.00
  •  543.65
  •  539.00
  •  540.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7183
  •  38.79
  •  664.00
  •  414.40

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,155.35
  • 18.33
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 10,773.21
  • 0.74%
  • 3.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.96%
  • 0.86%
  • 9.97%
  • FII
  • DII
  • Others
  • 0.43%
  • 5.20%
  • 10.58%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 10.94
  • -0.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.50
  • -9.35

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.30
  • -16.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.49
  • 25.18
  • 23.59

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.07
  • 7.30
  • 5.46

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.12
  • 17.07
  • 14.71

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
1,018.15
840.02
21.21%
1,127.06
789.29
42.79%
862.53
648.19
33.07%
853.31
741.35
15.10%
Expenses
775.92
652.49
18.92%
824.72
610.14
35.17%
711.54
546.77
30.14%
680.08
606.21
12.19%
EBITDA
242.23
187.53
29.17%
302.34
179.15
68.76%
150.99
101.42
48.88%
173.23
135.14
28.19%
EBIDTM
23.79%
22.32%
26.83%
22.70%
17.51%
15.65%
20.30%
18.23%
Other Income
3.52
0.33
966.67%
2.37
7.67
-69.10%
0.10
0.17
-41.18%
0.64
0.45
42.22%
Interest
5.95
0.82
625.61%
5.81
0.35
1,560.00%
1.57
0.89
76.40%
1.34
1.92
-30.21%
Depreciation
29.05
26.40
10.04%
28.63
25.65
11.62%
27.60
21.84
26.37%
31.57
21.84
44.55%
PBT
210.75
160.63
31.20%
270.27
160.82
68.06%
121.92
78.86
54.60%
140.96
111.83
26.05%
Tax
40.00
29.78
34.32%
70.30
36.57
92.23%
31.54
15.48
103.75%
38.52
16.49
133.60%
PAT
170.75
130.85
30.49%
199.97
124.24
60.95%
90.38
63.38
42.60%
102.44
95.34
7.45%
PATM
16.77%
15.58%
17.74%
15.74%
10.48%
9.78%
12.01%
12.86%
EPS
9.01
6.93
30.01%
10.61
6.45
64.50%
4.80
3.54
35.59%
4.98
4.94
0.81%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
3,861.05
3,130.81
3,134.61
3,165.99
2,056.13
1,863.22
1,520.35
1,465.41
1,202.05
Net Sales Growth
27.90%
-0.12%
-0.99%
53.98%
10.35%
22.55%
3.75%
21.91%
 
Cost Of Goods Sold
1,039.74
886.19
887.57
823.95
639.85
627.02
609.56
637.39
534.07
Gross Profit
2,821.31
2,244.62
2,247.04
2,342.04
1,416.28
1,236.20
910.78
828.02
667.97
GP Margin
73.07%
71.69%
71.68%
73.97%
68.88%
66.35%
59.91%
56.50%
55.57%
Total Expenditure
2,992.26
2,515.55
2,519.90
2,160.88
1,660.92
1,506.16
1,271.75
1,249.54
1,059.04
Power & Fuel Cost
-
70.35
64.20
58.89
43.31
32.07
26.66
29.57
24.58
% Of Sales
-
2.25%
2.05%
1.86%
2.11%
1.72%
1.75%
2.02%
2.04%
Employee Cost
-
622.81
558.83
472.85
306.76
247.00
193.79
168.46
149.21
% Of Sales
-
19.89%
17.83%
14.94%
14.92%
13.26%
12.75%
11.50%
12.41%
Manufacturing Exp.
-
244.53
289.79
209.91
263.38
272.44
191.95
183.83
145.34
% Of Sales
-
7.81%
9.24%
6.63%
12.81%
14.62%
12.63%
12.54%
12.09%
General & Admin Exp.
-
283.43
299.79
233.28
145.68
117.73
87.73
80.25
63.01
% Of Sales
-
9.05%
9.56%
7.37%
7.09%
6.32%
5.77%
5.48%
5.24%
Selling & Distn. Exp.
-
380.23
393.14
244.62
244.69
194.03
154.78
129.93
113.65
% Of Sales
-
12.14%
12.54%
7.73%
11.90%
10.41%
10.18%
8.87%
9.45%
Miscellaneous Exp.
-
28.01
26.58
117.38
17.26
15.86
7.27
20.11
29.17
% Of Sales
-
0.89%
0.85%
3.71%
0.84%
0.85%
0.48%
1.37%
2.43%
EBITDA
868.79
615.26
614.71
1,005.11
395.21
357.06
248.60
215.87
143.01
EBITDA Margin
22.50%
19.65%
19.61%
31.75%
19.22%
19.16%
16.35%
14.73%
11.90%
Other Income
6.63
34.87
2.58
8.83
12.09
4.44
16.71
16.31
21.01
Interest
14.67
3.40
5.23
5.43
3.81
10.40
23.98
37.55
27.59
Depreciation
116.85
105.46
82.97
72.21
44.41
40.49
34.97
33.65
29.59
PBT
743.90
541.27
529.09
936.30
359.07
310.61
206.35
160.98
106.84
Tax
180.36
120.36
122.19
216.12
76.35
75.10
41.10
30.85
21.46
Tax Rate
24.25%
22.24%
23.09%
23.08%
21.26%
24.18%
19.92%
19.16%
20.09%
PAT
563.54
420.72
406.99
720.18
282.72
235.51
165.25
130.13
85.39
PAT before Minority Interest
564.12
420.91
406.90
720.18
282.72
235.51
165.25
130.13
85.39
Minority Interest
0.58
-0.19
0.09
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
14.60%
13.44%
12.98%
22.75%
13.75%
12.64%
10.87%
8.88%
7.10%
PAT Growth
36.18%
3.37%
-43.49%
154.73%
20.05%
42.52%
26.99%
52.39%
 
Unadjusted EPS
29.40
21.89
21.39
38.19
15.01
12.49
8.77
6.90
4.53

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
2,220.14
1,902.33
1,597.36
884.64
675.57
502.94
395.00
296.73
Share Capital
37.70
37.70
37.70
37.70
37.70
37.70
37.70
11.00
Total Reserves
2,182.44
1,864.63
1,559.66
846.94
637.87
465.24
357.30
259.03
Non-Current Liabilities
597.10
94.15
84.02
72.44
94.32
103.25
122.07
150.80
Secured Loans
0.00
0.00
0.00
18.80
41.95
59.71
76.32
89.67
Unsecured Loans
500.00
0.00
0.00
0.00
10.27
10.83
18.54
38.81
Long Term Provisions
61.66
57.22
28.23
9.36
6.68
6.06
5.39
5.10
Current Liabilities
1,123.50
692.67
747.19
684.09
602.51
528.57
583.13
413.28
Trade Payables
759.32
500.73
565.65
324.94
288.44
239.96
209.15
138.57
Other Current Liabilities
142.89
81.28
51.80
44.56
60.62
69.25
151.60
84.90
Short Term Borrowings
207.78
88.51
113.71
219.70
25.42
70.11
138.43
146.28
Short Term Provisions
13.51
22.15
16.03
94.88
228.02
149.24
83.95
43.53
Total Liabilities
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81
Net Block
993.38
799.40
708.09
546.87
396.96
344.22
267.82
271.99
Gross Block
1,242.46
950.09
1,093.63
861.06
665.08
572.48
462.91
433.54
Accumulated Depreciation
249.08
150.69
385.54
314.19
268.12
228.26
195.09
161.55
Non Current Assets
2,116.31
1,316.80
917.30
750.43
515.81
415.66
364.35
308.30
Capital Work in Progress
1,010.15
396.28
92.52
83.14
20.67
32.26
58.24
26.50
Non Current Investment
41.64
49.88
53.43
2.26
3.36
3.30
3.30
3.26
Long Term Loans & Adv.
71.14
71.24
29.96
118.15
94.82
35.88
34.99
6.54
Other Non Current Assets
0.00
0.00
33.30
0.00
0.00
0.00
0.00
0.00
Current Assets
1,824.74
1,372.46
1,511.27
890.74
856.59
719.10
735.85
552.51
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
733.93
632.75
569.79
382.77
310.78
266.83
258.74
219.23
Sundry Debtors
526.34
338.82
350.48
361.17
273.37
232.87
199.33
201.97
Cash & Bank
89.92
159.60
450.83
26.83
23.96
16.11
47.09
6.29
Other Current Assets
474.55
7.56
7.09
0.00
248.48
203.29
230.68
125.02
Short Term Loans & Adv.
447.06
233.73
133.08
119.98
248.48
203.29
230.68
125.02
Net Current Assets
701.24
679.79
764.08
206.65
254.08
190.53
152.71
139.23
Total Assets
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
312.42
328.55
947.65
171.76
239.97
264.82
141.77
95.00
PBT
541.27
529.09
936.16
359.07
310.61
206.35
160.98
106.84
Adjustment
87.12
83.06
69.60
44.61
69.76
53.30
75.09
54.71
Changes in Working Capital
-180.85
-165.64
138.90
-162.50
-71.53
43.86
-61.59
-48.76
Cash after chg. in Working capital
447.54
446.51
1,144.66
241.18
308.84
303.51
174.48
112.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-135.12
-117.96
-197.01
-69.42
-68.87
-38.70
-32.71
-17.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-884.38
-485.91
-306.80
-255.61
-81.06
-67.02
-56.39
-56.82
Net Fixed Assets
-606.86
-121.60
-288.80
-200.26
-81.01
-83.59
-61.11
Net Investments
-195.85
-65.58
-4.13
0.00
-29.98
0.00
0.00
Others
-81.67
-298.73
-13.87
-55.35
29.93
16.57
4.72
Cash from Financing Activity
502.62
-128.88
-224.30
86.72
-151.06
-228.78
-44.58
-46.95
Net Cash Inflow / Outflow
-69.34
-286.24
416.55
2.86
7.86
-30.98
40.80
-8.77
Opening Cash & Equivalents
153.08
439.32
22.77
23.96
16.11
47.09
6.29
15.06
Closing Cash & Equivalent
83.74
153.08
439.32
26.83
23.96
16.11
47.09
6.29

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
117.78
100.92
84.74
46.93
35.84
26.68
20.95
49.10
ROA
12.70%
15.90%
35.39%
18.76%
18.79%
14.79%
13.27%
9.92%
ROE
20.42%
23.25%
58.03%
36.24%
39.97%
36.81%
39.14%
31.62%
ROCE
22.15%
28.87%
65.87%
37.54%
43.54%
32.05%
28.93%
21.52%
Fixed Asset Turnover
2.86
3.07
3.24
2.71
3.02
2.95
3.28
2.79
Receivable days
50.43
40.13
41.02
55.91
49.38
51.58
49.79
60.94
Inventory Days
79.67
70.01
54.91
61.11
56.34
62.73
59.30
66.15
Payable days
98.47
84.03
83.80
69.83
66.49
69.05
51.02
50.77
Cash Conversion Cycle
31.63
26.12
12.13
47.19
39.23
45.26
58.07
76.32
Total Debt/Equity
0.32
0.05
0.07
0.30
0.16
0.37
0.89
1.21
Interest Cover
160.20
102.16
173.43
95.30
30.87
9.60
5.29
4.87

News Update


  • Alembic Pharma gets USFDA’s nod for Azelastine Hydrochloride Ophthalmic Solution
    22nd Mar 2019, 10:49 AM

    Azelastine Hydrochloride Ophthalmic Solution 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis

    Read More
  • Alembic Pharmaceuticals raises Rs 150 crore via NCDs
    19th Mar 2019, 11:15 AM

    The NCD Committee of the Company at its meeting held on March 19, 2019 has allotted the same

    Read More
  • Alembic Pharmaceuticals planning to raise Rs 150 crore via NCDs
    13th Mar 2019, 16:29 PM

    The company’s NCD committee will consider the same in the meeting to be held on March 19, 2019

    Read More
  • Alembic Pharmaceuticals’ JV receives USFDA approval for Clobetasol Propionate Ointment
    5th Mar 2019, 14:46 PM

    Clobetasol Propionate Ointment USP, 0.05%, has an estimated market size of US$ 63 million for twelve months ending December 2018 according to IQVIA

    Read More
  • Alembic Pharma gets USFDA’s nod for Acetazolamide Extended-Release Capsules
    20th Feb 2019, 11:24 AM

    Alembic has a cumulative total of 87 ANDA approvals from USFDA

    Read More
  • Alembic gets USFDA’s nod for Moxifloxacin Ophthalmic Solution
    15th Feb 2019, 10:55 AM

    The company has a cumulative total of 86 ANDA approvals (73 final approvals and 13 tentative approvals) from USFDA

    Read More
  • Alembic Pharma’s arm receives USFDA approval for Fenofibrate Tablets
    12th Feb 2019, 16:45 PM

    Fenofibrate Tablets USP, 54 mg and 160 mg have an estimated market size of $ 92 million for twelve months

    Read More
  • Alembic Pharma’s JV completes USFDA inspection at Karakhadi facility
    11th Feb 2019, 16:24 PM

    The inspection was carried out from February 04, 2019 to February 08, 2019

    Read More
  • Alembic Pharmaceuticals reports 30% rise in Q3 consolidated net profit
    22nd Jan 2019, 15:04 PM

    Total consolidated income of the company increased by 21.58% at Rs 1021.67 crore for Q3FY19

    Read More
  • Alembic Pharma - Quarterly Results
    22nd Jan 2019, 13:48 PM

    Read More
  • Alembic Pharma gets USFDA nod for Pramipexole Dihydrochloride Extended-Release Tablets
    3rd Jan 2019, 10:52 AM

    Alembic has a cumulative total of 84 ANDA approvals (71 final approvals and 13 tentative approvals) from USFDA

    Read More
  • USFDA completes inspection at Alembic Pharma’s API Facility in Gujarat
    20th Dec 2018, 10:22 AM

    This was a scheduled inspection and at the end of the inspection, there were zero 483s

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.